VCH-916

VCH-916 is a novel non-nucleoside inhibitor of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase. It acts as an allosteric inhibitor targeting the NS5B polymerase and has demonstrated sub-micromolar inhibitory activity against HCV replicons of genotypes 1a and 1b. The compound was developed for oral administration and exhibits high bioavailability with favorable absorption, distribution, metabolism, and excretion (ADME) properties. Preclinical studies showed extensive plasma protein binding (>98%) and low potential for drug-drug interactions via CYP inhibition or induction. Clinical development reached Phase 1 trials in patients with chronic hepatitis C infection to evaluate safety, tolerability, pharmacokinetics, and antiviral efficacy[1][2][4][7].

Other names

potassium 5-(cyclohex-1-en-1-yl)-3-(N-(4-methoxycyclohexyl)-4-methylcyclohexanecarboxamido)thiophene-2-carboxylate2-Thiophenecarboxylic acid, 5-(1-cyclohexen-1-yl)-3-[N-(4-methoxycyclohexyl)-4-methylcyclohexanecarboxamido]CAS Number 1200133-34-1